Ceftobiprole medocaril

Rev Esp Quimioter. 2022 Apr;35 Suppl 1(Suppl 1):25-27. doi: 10.37201/req/s01.05.2022. Epub 2022 Apr 22.


Ceftobiprole medocaril is a broad-spectrum 5th-generation cephalosporin with activity against Gram-positives such as methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae, and against Gram-negatives such as Pseudomonas aeruginosa. The recommended dose is 500 mg every 8 h in 2-hour infusions. Various clinical trials have demonstrated its usefulness in the treatment of community-acquired pneumonia and nosocomial pneumonia, with the exception of ventilator-associated pneumonia. In summary, it is a very useful antibiotic for the treatment of pneumonia.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Cephalosporins / pharmacology
  • Cephalosporins / therapeutic use
  • Community-Acquired Infections* / drug therapy
  • Humans
  • Methicillin-Resistant Staphylococcus aureus*


  • Anti-Bacterial Agents
  • Cephalosporins
  • ceftobiprole medocaril